188 related articles for article (PubMed ID: 27512044)
21. Microtubules dual chemo and thermo-responsive depolymerization.
Li Z; Alisaraie L
Proteins; 2015 May; 83(5):970-81. PubMed ID: 25739855
[TBL] [Abstract][Full Text] [Related]
22. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids.
Coderch C; Morreale A; Gago F
Anticancer Agents Med Chem; 2012 Mar; 12(3):219-25. PubMed ID: 22044006
[TBL] [Abstract][Full Text] [Related]
23. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and evaluation of C2 functionalized analogs of the α-tubulin-binding natural product pironetin.
Huang DS; Wong HL; Georg GI
Bioorg Med Chem Lett; 2018 Sep; 28(16):2789-2793. PubMed ID: 29138028
[TBL] [Abstract][Full Text] [Related]
25. Direct coupling of catharanthine and vindoline to provide vinblastine: total synthesis of (+)- and ent-(-)-vinblastine.
Ishikawa H; Colby DA; Boger DL
J Am Chem Soc; 2008 Jan; 130(2):420-1. PubMed ID: 18081297
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.
Hall JJ; Sriram M; Strecker TE; Tidmore JK; Jelinek CJ; Kumar GD; Hadimani MB; Pettit GR; Chaplin DJ; Trawick ML; Pinney KG
Bioorg Med Chem Lett; 2008 Sep; 18(18):5146-9. PubMed ID: 18710804
[TBL] [Abstract][Full Text] [Related]
27. QM and QM/MD simulations of the Vinca alkaloids docked to tubulin.
Kelly EB; Tuszynski JA; Klobukowski M
J Mol Graph Model; 2011 Sep; 30():54-66. PubMed ID: 21798777
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors.
Sri Ramya PV; Angapelly S; Guntuku L; Singh Digwal C; Nagendra Babu B; Naidu VGM; Kamal A
Eur J Med Chem; 2017 Feb; 127():100-114. PubMed ID: 28038323
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors.
Khelifi I; Naret T; Renko D; Hamze A; Bernadat G; Bignon J; Lenoir C; Dubois J; Brion JD; Provot O; Alami M
Eur J Med Chem; 2017 Feb; 127():1025-1034. PubMed ID: 28166995
[TBL] [Abstract][Full Text] [Related]
30. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
Shi Q; Chen K; Morris-Natschke SL; Lee KH
Curr Pharm Des; 1998 Jun; 4(3):219-48. PubMed ID: 10197041
[TBL] [Abstract][Full Text] [Related]
31. Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents.
Wang S; Fang K; Dong G; Chen S; Liu N; Miao Z; Yao J; Li J; Zhang W; Sheng C
J Med Chem; 2015 Aug; 58(16):6678-96. PubMed ID: 26226379
[TBL] [Abstract][Full Text] [Related]
32. Tubulins - the target for anticancer therapy.
Vindya NG; Sharma N; Yadav M; Ethiraj KR
Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
[TBL] [Abstract][Full Text] [Related]
33. High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.
Radakovic A; Boger DL
Bioorg Med Chem Lett; 2018 Mar; 28(5):863-865. PubMed ID: 29439899
[TBL] [Abstract][Full Text] [Related]
34. Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.
Lukesh JC; Carney DW; Dong H; Cross RM; Shukla V; Duncan KK; Yang S; Brody DM; Brütsch MM; Radakovic A; Boger DL
J Med Chem; 2017 Sep; 60(17):7591-7604. PubMed ID: 28857558
[TBL] [Abstract][Full Text] [Related]
35. Triazole tethered C5-curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies.
Singh H; Kumar M; Nepali K; Gupta MK; Saxena AK; Sharma S; Bedi PMS
Eur J Med Chem; 2016 Jun; 116():102-115. PubMed ID: 27060762
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of hybrid molecules targeting the vinca domain of tubulin.
Gherbovet O; Sánchez-Murcia PA; García Alvarez MC; Bignon J; Thoret S; Gago F; Roussi F
Org Biomol Chem; 2015 Mar; 13(10):3144-54. PubMed ID: 25634805
[TBL] [Abstract][Full Text] [Related]
37. Double-sides sticking mechanism of vinblastine interacting with α,β-tubulin to get activity against cancer cells.
Zhou X; Xu Z; Li A; Zhang Z; Xu S
J Biomol Struct Dyn; 2019 Sep; 37(15):4080-4091. PubMed ID: 30451089
[TBL] [Abstract][Full Text] [Related]
38. Structural basis for the regulation of tubulin by vinblastine.
Gigant B; Wang C; Ravelli RB; Roussi F; Steinmetz MO; Curmi PA; Sobel A; Knossow M
Nature; 2005 May; 435(7041):519-22. PubMed ID: 15917812
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of paclitaxel-mimics possessing only the oxetane D-ring and side chain structures.
Chen XX; Gao F; Wang Q; Huang X; Wang D
Fitoterapia; 2014 Jan; 92():111-5. PubMed ID: 24211350
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and Cytotoxic Activity of New Vindoline Derivatives Coupled to Natural and Synthetic Pharmacophores.
Keglevich A; Dányi L; Rieder A; Horváth D; Szigetvári Á; Dékány M; Szántay C; Latif AD; Hunyadi A; Zupkó I; Keglevich P; Hazai L
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
